Dale Anderson
Psychiatry · St Louis, MONPI 1144321746
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $966 and has fallen 70.2% since, to $288 in 2025.
Across 213 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Takeda Pharmaceuticals U.S.A., Inc.$523
- Otsuka America Pharmaceutical, Inc.$473
- Corium, LLC$438
- Ironshore Pharmaceuticals Inc.$308
- Axsome Therapeutics, Inc.$245
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,852100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,852 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 21 | $11,959 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $11,393 |
| Methylphenidate ErMethylphenidate Hcl | 46 | $9,614 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 170 | $6,952 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 15 | $2,359 |
| Methylphenidate Hcl | 60 | $2,301 |
| Buspirone Hcl | 57 | $1,629 |
| Methylphenidate Hcl Er (Cd)Methylphenidate Hcl | 11 | $1,596 |
| Clorazepate Dipotassium | 13 | $1,489 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,294 |
| Lamotrigine | 59 | $1,036 |
| Hydroxyzine Hcl | 25 | $1,031 |
| Paroxetine Hcl | 35 | $1,004 |
| Bupropion XlBupropion Hcl | 55 | $923 |
| Atomoxetine Hcl | 20 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $523 | $23,35242 claims |
| Almatica Pharma LLCSertraline Hcl | $64 | $30820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in St Louis
- Thomas NowotnySt Louis$16K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.